Logo - springer
Slogan - springer

Biomedical Sciences - Pharmacology & Toxicology | Current Pharmacology Reports

Current Pharmacology Reports

Current Pharmacology Reports

Editor-in-Chief: Ah-Ng T. Kong

ISSN: 2198-641X (electronic version)

Journal no. 40495

80,33 € Personal Rate e-only
Get Subscription

Online subscription, valid from January through December of current calendar year

Immediate access to this year's issues via SpringerLink

Volume(-s) with issue(-s) per annual subscription

Automatic annual renewal

More information: >> FAQs // >> Policy

Learn more about the metrics of this journal

This bi-monthly journal delivers cutting-edge reviews on all aspects of pharmacology, contributed by international experts.

  • Presents cutting-edge reviews on subjects pertinent to all aspects of pharmacology
  • Offers incisive, insightful, and balanced contributions by international leading experts
  • Benefits a wide readership of scientists and translational investigators in academia and in industry

This journal presents incisive reviews by international experts, on all aspects of pharmacology, including drug discovery and development. Coverage includes epigenetics, drug design, toxicology, absorption, distribution, metabolism and elimination and more.

Related subjects » Biomedical Sciences - Cancer Research - Human Genetics - Pharmacology & Toxicology

Abstracted/Indexed in 

SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, EBSCO Discovery Service, OCLC WorldCat Discovery Service, ProQuest-ExLibris Primo, ProQuest-ExLibris Summon, Reaxys

Subscription information 

2019. Volume 5 (6 issues each). 80,33 € suggested net price* plus shipping charges. If an online version exists, subscription includes both the print edition and online access via SpringerLink (Basic SpringerLink License).

Read this Journal on Springerlink

For authors and editors

  • Aims and Scope

    Aims and Scope

    Close

    Current Pharmacology Reports will:

    • publish cutting-edge reviews on subjects pertinent to all aspects of pharmacology, including drug discovery and development.
    • provide incisive, insightful, and balanced contributions from international leading experts.
    • interest a wide readership of basic scientists and translational investigators in academia and in industry. 

    The Current Pharmacology Reports journal accomplishes its goal by appointing international authorities to serve as Section Editors in key subject areas, such as: epigenetics and epigenomics, chemoinformatics and rational drug design and target discovery, drug delivery and biomaterial, pharmacogenomics and molecular targets and biomarkers, chemical/drug/molecular toxicology, absorption, distribution, metabolism and elimination (ADME), pharmacokinetics (PK) and pharmacodynamics (PD), Modeling & Simulation (M&S) and pharmacometrics, and other related topics in pharmacology including neurology/central nervous system (CNS), cardiovascular, metabolic diseases, cancer, among others.

    Section Editors for Current Pharmacology Reports select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided. This journal publishes on a bi-monthly schedule.

  • Open Choice - Your Way to Open Access
  • Ethical Requirements

    Compliance with Ethical Requirements

    Close

  • Instructions for Authors

Alerts for this journal

 

Get the table of contents of every new issue published in Current Pharmacology Reports.


Additional information